5-HIAA Screening in Neuroendocrine Tumors

Primary Clinical Utility

The National Comprehensive Cancer Network recommends 5-HIAA as a diagnostic tool for neuroendocrine tumors (NETs), particularly those originating from the small intestine that produce excess serotonin, with high specificity (approximately 90%) for detecting carcinoid syndrome 1, 2
5-HIAA is useful for monitoring treatment response in patients with known carcinoid tumors, with decreasing levels indicating successful treatment and increasing levels suggesting treatment failure, according to the National Comprehensive Cancer Network 1, 3

Diagnostic Performance

The American Thoracic Society notes that 5-HIAA has limited sensitivity (35.1%) for detecting NETs and should be combined with other biomarkers, such as chromogranin A, for comprehensive evaluation 2
Measuring 5-HIAA alongside other NET biomarkers like chromogranin A and neuron-specific enolase is recommended for optimal diagnostic accuracy, as stated by the American Thoracic Society 2

Collection and Interpretation Considerations

The National Comprehensive Cancer Network advises that 5-HIAA requires a 24-hour urine collection with specific dietary and medication restrictions, including avoidance of certain foods and substances like avocados, bananas, and coffee, for accurate results 1, 3
Patients should avoid medications that can falsely elevate 5-HIAA levels, such as acetaminophen, ephedrine, and phenobarbital, as recommended by the National Comprehensive Cancer Network 1, 3

Alternative Testing Options

Chromogranin A is considered a reliable general biomarker for NETs, including non-serotonin producing tumors, and should be used alongside 5-HIAA, according to the European Neuroendocrine Tumor Society 2, 4
Somatostatin receptor scintigraphy (Octreoscan) can detect bronchopulmonary NETs that may be missed by other diagnostic studies, as noted by the American Thoracic Society 2

Key Pitfalls to Avoid

Relying solely on 5-HIAA for diagnosis without considering other biomarkers may miss NETs that don't produce significant serotonin, as warned by the European Neuroendocrine Tumor Society and the British Society of Gastroenterology 2, 5
Failing to provide proper dietary and medication instructions before collection can lead to false positive results, according to the National Comprehensive Cancer Network 1, 3

Diagnostic Approach for Carcinoid Tumors

Biochemical Markers

The European Society for Medical Oncology recommends chromogranin A as a pan-neuroendocrine marker that should be routinely measured in all suspected cases, particularly valuable for non-functioning tumors where hormonal markers may be negative 6
The British Society of Gastroenterology suggests that urinary 5-HIAA has limited sensitivity of 35.1% for general NET detection but reaches approximately 70% sensitivity specifically for midgut carcinoids with carcinoid syndrome 7
For midgut carcinoids, urinary 5-HIAA is usually raised in 70% of patients, while for foregut carcinoids, urinary 5-HIAA is sometimes raised, and chromogranin A is more reliable 7
For hindgut carcinoids, urinary 5-HIAA is not raised, and chromogranin A should be relied upon 7
The European Neuroendocrine Tumor Society recommends that pancreatic NETs should be diagnosed using chromogranin A as the primary marker, regardless of functional status 6

Diagnostic Algorithm

The American College of Gastroenterology suggests that for initial screening, chromogranin A should be measured in all suspected cases as the primary marker, and for midgut carcinoids or suspected carcinoid syndrome, urinary 5-HIAA or preferably fasting plasma 5-HIAA should be added for greater convenience and comparable accuracy 6, 7
Combined testing with chromogranin A plus serotonin metabolites provides optimal diagnostic accuracy, as recommended by the European Society for Medical Oncology 6

Diagnostic Approach for Carcinoid Syndrome

Primary Diagnostic Approach

Urinary 5-HIAA (24-hour collection) remains the gold standard for diagnosing carcinoid syndrome with approximately 90% specificity and 73% sensitivity, as recommended by the American College of Chest Physicians 8, 9
Serum chromogranin A should be measured in all suspected cases as it has the highest reliability and accuracy among NET biomarkers, elevated in 75% of carcinoid tumors, according to the American College of Chest Physicians 8, 9

Clinical Indications for Testing

Suspected carcinoid syndrome: skin flushing of upper thorax, secretory diarrhea, bronchoconstriction, warrants testing, as suggested by the American College of Chest Physicians 8, 9, 10
Before invasive procedures in patients with known or suspected bronchopulmonary NETs to prevent carcinoid crisis, as recommended by the American College of Chest Physicians 8, 9

Critical Collection Requirements

Dietary restrictions for 48 hours before and during urinary 5-HIAA collection: avoid avocados, bananas, coffee, alcohol, pineapples, plums, walnuts, tomatoes, as advised by the American College of Chest Physicians 8, 9

Complementary Biomarkers

Chromogranin A: Most reliable pan-neuroendocrine marker, but can be falsely elevated by proton pump inhibitors, renal/hepatic insufficiency, atrophic gastritis, according to the American College of Chest Physicians 8, 9
Neuron-specific enolase: Highly specific but low sensitivity (32.9%), as reported by the American College of Chest Physicians 8, 9

Imaging Adjuncts

Somatostatin receptor scintigraphy (Octreoscan): Detects up to 80% of bronchopulmonary NETs that express somatostatin receptors, useful for tumors missed by other studies, as suggested by the American College of Chest Physicians 8, 9

Management Implications

Recognition of carcinoid syndrome before invasive procedures allows prophylactic IV octreotide to prevent carcinoid crisis, as recommended by the American College of Chest Physicians 8, 9

Carcinoid Tumor Diagnosis and Management

Diagnostic Markers

The European Society of Medical Oncology recommends measuring baseline chromogranin A (CgA) and 24-hour urinary 5-HIAA in all suspected carcinoid tumor cases as first-line markers 11, 12
CgA should be measured in plasma/serum as the primary screening marker, regardless of whether the tumor is functioning or non-functioning, and is particularly useful for gastric carcinoids with metastases 11, 13
For midgut carcinoids, urinary 5-HIAA is elevated in 70% of patients, while for foregut carcinoids, urinary 5-HIAA is only sometimes raised, making CgA more reliable 12, 14
For hindgut carcinoids, urinary 5-HIAA is typically not elevated; rely on CgA instead 12, 14

Location-Specific Testing Algorithm

For midgut carcinoids, measure both CgA and 24-hour urinary 5-HIAA, as 5-HIAA sensitivity reaches 70% for this location 12, 14
For foregut carcinoids, prioritize CgA over 5-HIAA, as 5-HIAA is only occasionally elevated 14
For hindgut carcinoids, use CgA exclusively, as 5-HIAA is not raised in these tumors 12, 14

Additional Markers to Consider

Pancreatic polypeptide is elevated in 50% of carcinoid tumors and 80% of pancreatic neuroendocrine tumors 11, 15
Tachykinins (neurokinin A and B) are raised in midgut carcinoids 12, 14

Critical Pre-Collection Requirements for 5-HIAA

Dietary restrictions for 48 hours before and during collection: avoid certain foods and substances that may interfere with test results 15, 13
Medications causing false positives or false negatives should be avoided or considered when interpreting results 15, 13

Monitoring Treatment Response

Measure CgA every 3-6 months during follow-up for treated carcinoid tumors 16

Additional Baseline Tests

Other markers that may be appropriate depending on clinical presentation include thyroid function tests, parathyroid hormone, calcium, calcitonin, prolactin, alpha-fetoprotein, CEA, and beta-HCG 11, 12

Baseline Biochemical Testing for Suspected Carcinoid Tumors

Baseline Testing

Order both plasma chromogranin A (CgA) and a 24‑hour urinary 5‑hydroxyindoleacetic acid (5‑HIAA) as initial investigations for any patient with suspected carcinoid tumor, because CgA is the primary pan‑neuroendocrine marker while 5‑HIAA provides specific information on serotonin‑producing lesions. [17][18]19

Location‑Specific Interpretation of 5‑HIAA

In midgut carcinoids, urinary 5‑HIAA is elevated in approximately 70 % of patients, making it a highly useful adjunct to CgA. [17][20]
In foregut carcinoids, 5‑HIAA is only intermittently elevated; CgA should be given priority in interpretation. [17][20]
In hindgut carcinoids, 5‑HIAA is typically not elevated; diagnosis relies almost exclusively on CgA. [17][20]

Pre‑Analytical Considerations for 5‑HIAA

Patients must avoid certain foods for 48 hours before and during urine collection to prevent false‑positive results: avocados, bananas, pineapples, plums, walnuts, tomatoes, and eggplant. [17][19]21

Medication Interferences with 5‑HIAA

False‑positive urinary 5‑HIAA can occur with use of paracetamol (acetaminophen), fluorouracil, methysergide, naproxen, and caffeine. [17][19]21
False‑negative urinary 5‑HIAA can occur with levodopa, aspirin, ACTH, methyldopa, and phenothiazines. [17][19]21

Factors Causing False‑Positive CgA

Chronic atrophic gastritis may raise CgA levels independent of neuroendocrine tumor presence. 19

Additional Biochemical Markers

Tachykinins (neurokinin A and B) are specifically elevated in midgut carcinoids and can aid diagnosis when used alongside CgA and 5‑HIAA. [17][20]

Secondary Baseline Tests for Specific Clinical Contexts

For patients being screened for multiple endocrine neoplasia type 1 (MEN 1), include thyroid function tests, parathyroid hormone, and calcium measurements. 17
Measure calcitonin when medullary thyroid carcinoma is a concern. 17
Consider prolactin, α‑fetoprotein, carcinoembryonic antigen (CEA), and β‑human chorionic gonadotropin (β‑HCG) as additional markers in appropriate clinical scenarios. 19

Syndrome‑Specific Testing

Carcinoid syndrome (episodic upper‑thoracic flushing and secretory diarrhea) warrants simultaneous ordering of CgA and 5‑HIAA, as recommended by the NCCN guidelines. [22][23]19
In bronchopulmonary or thymic carcinoids presenting with Cushing’s‑type features, add plasma ACTH measurement to detect ectopic ACTH production, per NCCN recommendations. [22][23]

Diagnostic Pitfalls

Approximately 30 % of midgut carcinoids and the majority of foregut and hindgut carcinoids may have normal urinary 5‑HIAA despite active disease; therefore, reliance on 5‑HIAA alone can miss a substantial proportion of cases. [17][20]